Pierpaolo Moscariello; David Y. W. Ng; Malin Jansen; Tanja Weil; Heiko J. Luhmann; Jana Hedrich
Index: 10.1002/advs.201700897
Full Text: HTML
Neurological disorders are undoubtedly among the most alarming diseases humans might face. In treatment of neurological disorders, the blood‐brain barrier (BBB) is a challenging obstacle preventing drug penetration into the brain. Advances in dendrimer chemistry for central nervous system (CNS) treatments are presented here. A poly(amido)amine (PAMAM) dendrimer bioconjugate with a streptavidin adapter for the attachment of dendrons or any biotinylated drug is constructed. In vitro studies on porcine or murine models and in vivo mouse studies are performed and reveal the permeation of dendronized streptavidin (DSA) into the CNS. The bioconjugate is taken up mainly by the caveolae pathway and transported across the BBB via transcytosis escaping from lysosomes. After transcytosis DSA are delivered to astrocytes and neurons. Furthermore, DSA offer high biocompatibility in vitro and in vivo. In summary, a new strategy for implementing therapeutic PAMAM function as well as drug delivery in neuropathology is presented here.
|
Multicolor T‐Ray Imaging Using Multispectral Metamaterials
2018-03-25 [10.1002/advs.201700982] |
|
Acorn Barnacles Secrete Phase‐Separating Fluid to Clear Surf...
2018-03-14 [10.1002/advs.201700762] |
|
Trojan‐Horse‐Like Stimuli‐Responsive Microcapsules
2018-03-13 [10.1002/advs.201700960] |
|
Microstructured Elastomer‐PEG Hydrogels via Kinetic Capture ...
2018-03-12 [10.1002/advs.201701010] |
|
Green‐Light‐Activated Photoreaction via Genetic Hybridizatio...
2018-03-12 [10.1002/advs.201700863] |
Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer
Copyright © 2026 ChemSrc All Rights Reserved